Harvard Catalyst Profiles
Contact, publication, and social network information about Harvard faculty and fellows.
Open Source Software
to edit your profile (add a photo, awards, links to other websites, etc.)
Edit My Profile
My Person List (
Return to Top
Search Result Details
Back to Search Results
This page shows the details of why an item matched the keywords from your search.
One or more keywords matched the following items that are connected to
Thrombopoietin and thrombopoietin mimetics in the treatment of thrombocytopenia.
What is the potential for thrombopoietic agents in acute leukemia?
New drugs for familiar therapeutic targets: thrombopoietin receptor agonists and immune thrombocytopenic purpura.
New thrombopoietic agents: introduction.
New thrombopoietic growth factors.
Thrombopoietin levels in patients with disorders of platelet production: diagnostic potential and utility in predicting response to TPO receptor agonists.
Managing thrombocytopenia associated with cancer chemotherapy.
Treatment patterns and clinical outcomes in patients with chronic immune thrombocytopenia (ITP) switched to eltrombopag or romiplostim.
Relative potency of the thrombopoietin receptor agonists eltrombopag, avatrombopag and romiplostim in a patient with chronic immune thrombocytopenia.
An alternative intermittent eltrombopag dosing protocol for the treatment of chronic immune thrombocytopenia.
Thrombopoietin level predicts response to treatment with eltrombopag and romiplostim in immune thrombocytopenia.
Preparing patients with immune thrombocytopenia for surgery: what are the options?